New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 30, 2012
09:00 EDTARII, KALU, CERN, EME, DG, PPG, BSYBY, KFT, IDIX, HMSY, CHK, CMP, CPN, AZN, MDTOn The Fly: Analysts Upgrade Summary
Today's noteworthy upgrades include: American Railcar (ARII) upgraded to Neutral from Sell at UBS...AstraZeneca (AZN) upgraded to Buy from Hold at Jefferies and to Neutral from Underweight at JPMorgan...Calpine (CPN) upgraded to Buy from Hold at Jefferies...Chesapeake (CHK) upgraded to Outperform from Market Perform at BMO Capital...Compass Minerals (CMP) upgraded to Buy from Hold at KeyBanc...HMS Holdings (HMSY) upgraded to Buy from Hold at Jefferies...Idenix (IDIX) upgraded to Market Perform from Underperform at JMP Securities...Kraft Foods (KFT) upgraded to Overweight from Neutral at JPMorgan...British Sky Broadcasting (BSYBY) upgraded to Buy from Neutral at Citigroup...PPG Industries (PPG) upgraded to Outperform from Neutral at Credit Suisse...Dollar General (DG) upgraded to Strong Buy from Outperform at Raymond James...EMCOR Group (EME) upgraded to Buy from Hold at Stifel Nicolaus...Cerner (CERN) upgraded to Outperform from Market Perform at Raymond James...Kaiser Aluminum (KALU) upgraded to Buy from Hold at Dahlman Rose...Medtronic (MDT) upgraded to Buy from Neutral at Lazard Capital.
News For ARII;AZN;CPN;CMP;CHK;HMSY;IDIX;KFT;BSYBY;PPG;DG;EME;CERN;KALU;MDT From The Last 14 Days
Check below for free stories on ARII;AZN;CPN;CMP;CHK;HMSY;IDIX;KFT;BSYBY;PPG;DG;EME;CERN;KALU;MDT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 9, 2014
09:36 EDTCHKActive equity options trading on open
Subscribe for More Information
09:20 EDTDGBofA/Merrill's retail analysts hold an analyst/industry conference call
Subscribe for More Information
07:23 EDTIDIXEuropean Association for the Study of the Liver to hold annual meeting
Subscribe for More Information
April 8, 2014
11:47 EDTIDIXIdenix price target raised to $9 from $6 at Leerink
Leerink raised Idenix's price target to $9 from $6 citing positive IDX21437 data.
11:03 EDTAZNPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.
07:26 EDTMDTElsevier Business Intelligence to hold a conference
Subscribe for More Information
April 7, 2014
16:34 EDTAZNMyriad Genetics submits premarket approval to FDA for BRACAnalysis
Subscribe for More Information
16:28 EDTIDIXOn The Fly: Closing Wrap
Subscribe for More Information
13:31 EDTIDIXIdenix risk/reward remains favorable, says UBS
UBS said Idenix's IDX21437 update this morning supports its favorable risk/reward thesis. Shares are Buy rated with an $11 price target.
11:05 EDTPPG High option volume stocks: EXC QCOR SQQQ GNK PPG
Subscribe for More Information
10:00 EDTCMPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:52 EDTCMPCompass Minerals initiated with a Buy at Monness Crespi
Subscribe for More Information
07:58 EDTMDTMedtronic data positive for C.R. Bard, says Barclays
Barclays said Medtronic's (MDT) better than expected drug coated balloon data could have a positive class effect that benefits C.R. Bard (BCR). The firm reiterates its Overweight rating C.R. Bard and raised its price target to $165 from $160. Note that BofA/Merrill downgraded C.R. Bard to Neutral from Buy following the Medtronic's news.
07:38 EDTMDTMedtronic data should lead to approval of drug-coated balloon, says Wells Fargo
Subscribe for More Information
07:27 EDTAZNAmerican Association of Cancer Research to hold annual meeting
Subscribe for More Information
07:15 EDTIDIXIdenix announces promising clinical data, continued progress in HCV programs
Idenix Pharmaceuticals announced continued progress of the Company's program to develop nucleotide prodrug inhibitors for the treatment of hepatitis C virus, or HCV, infection. Idenix is reporting potent antiviral activity of mean maximum 4.2-4.3 log10 IU/mL reductions for patients infected with HCV genotype 1, 2 or 3 receiving 300 mg once daily of IDX21437 in the seven-day proof-of-concept portion of a phase I/II clinical trial. Based on this progress, the Company's goal is to initiate a combination clinical trial of IDX21437 and samatasvir, a pan-genotypic NS5A inhibitor, in mid-2014. In addition, Idenix has selected a follow-on uridine-based nucleotide prodrug, IDX21459, from its ongoing nucleotide discovery program and initiated enrollment for the healthy volunteer portion of a phase I clinical trial. In January, Idenix initiated the seven-day proof-of-concept portion of a phase I/II clinical trial for IDX21437. The trial completed enrollment of 44 treatment-nave, genotype, or GT, 1, 2 or 3 HCV-infected patients. Patients were randomized to receive once-daily doses of placebo, 50 mg, 150 mg, or 300 mg of IDX21437 for seven days. In April 2014, Idenix initiated enrollment for the healthy volunteer portion of a phase I clinical trial of IDX21459 in Europe. This portion of the study is expected to enroll approximately 50 healthy volunteers and will evaluate once-daily doses of IDX21459 ranging from 10 mg 300 mg. The proof-of-concept portion of the study is expected to enroll a total of 40 treatment-nave, genotype 1 HCV-infected patients who will receive once-daily doses of placebo, 50 - 300 mg of IDX21459 for seven days. IDX21459 has shown a favorable preclinical profile including potent, pan-genotypic activity and favorable safety with respect to cardiac, mitochondrial and genotoxicity assessments.
05:48 EDTAZNMyriad Genetics submits premarket approval to FDA for BRACAnalysis
Subscribe for More Information
April 3, 2014
11:19 EDTPPGRPM hits 52-week high after raising full year profit outlook
Shares of specialty chemical, paint, and coating maker RPM (RPM) are rallying after the company raised its fiscal 2014 profit outlook. WHAT'S NEW: This morning, RPM reported third quarter earnings per share of 12c and revenue of $863.4M, compared to expectations of 9c and $877.67M, respectively. RPM raised its FY14 EPS view to $2.10-$2.15 from $2.05-$2.10, compared to consensus of $2.11. It also forecast FY14 industrial sales growth of 4%-6% and consumer sales growth of 8%-10%. The company cited stronger than anticipated leverage in its industrial segment, resulting from solid performance in Europe and businesses serving U.S. construction markets, as the reason for the improved outlook. PRICE ACTION: In late morning trading, RPM rose $2.03, or 4.8%, to $44.20 on heavy trading volume. Earlier in the session, the stock hit a fresh 52-week high of $45.47. Including today's advance, the stock is up approximately 43% over the past twelve months. OTHERS TO WATCH: Other companies in the paint and coatings space include PPG Industries (PPG), Valspar (VAL), and Sherwin Williams (SHW).
10:00 EDTDGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:35 EDTDGDollar General initiated with a Hold at Jefferies
Target $56.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use